Inhibition of antigen-dependent B-cell receptor (BCR) signaling is considered a promising therapeutic approach in CLL, but experimental in vivo evidence to support this view is still lacking. We have now investigated whether inhibition of BCR signaling with the selective Syk inhibitor fostamatinib disodium (R788) will affect the growth of the leukemias that develop in the Eμ-TCL1 transgenic mouse model of CLL. Similar to human CLL these leukemias express stereotyped BCRs that react with autoantigens exposed on the surface of senescent or apoptotic cells, suggesting that they are antigen-driven. We show that R788 effectively inhibits BCR signaling in vivo, resulting in reduced proliferation and survival of the malignant B-cells and significantly prolonged survival of the treated animals. The growth-inhibitory effect of R788 occurs despite the relatively modest cytotoxic effect in vitro and is independent of basal Syk activity, suggesting that R788 functions primarily by inhibiting antigen-dependent BCR signals. Importantly, the effect of R788 was found to be selective for the malignant clones, as no disturbance in the production of normal B-lymphocytes was observed.
INTRODUCTION
The proliferation and survival of chronic lymphocytic leukemia B-cells is regulated by intracellular signaling pathways that are activated by various stimuli from the microenvironment. Among these, antigenic stimuli that are propagated through the B-cell receptor (BCR) are considered to play a key role in the initiation, maintenance and evolution of the malignant clone [1] [2] [3] .
A role for antigen stimulation and selection in the pathogenesis of CLL was postulated many years ago, based on observations that the leukemic cells express a highly restricted IgV H gene repertoire 4 . This hypothesis was subsequently reinforced with the identification of CLL subsets with nearly identical (stereotyped) B-cell receptors, suggesting that the malignant clones are selected by sets of structurally similar antigens 5 . The possibility that antigen stimulation may also be involved in disease progression is supported by the strong association between the clinical course in CLL and certain BCR-related features, such as IgV H gene mutation status and expression of the protein tyrosine kinase ZAP-70 [6] [7] [8] . In addition, immunophenotyping and gene expression profiling studies have shown that CLL cells display features of lymphocytes that are continuously triggered by antigen in vivo. This especially refers to leukemic B-cells from the poor prognosis subset, which more often exhibit a surface phenotype of recently activated B-lymphocytes and show increased expression of genes that are induced in normal B-cells by BCR engagement 9, 10 .
The evidence that BCR signals may be involved in the initiation and evolution of CLL raised the possibility that inhibition of this pathway could be a therapeutically effective strategy in CLL. Previous studies by our group showed that sustained engagement of the BCR induces a powerful antiapoptotic program in CLL cells, which is characterized by induction of several apoptosis regulatory proteins, including Mcl-1, Bcl-xL and XIAP 11, 12 .
Transduction of the prosurvival BCR signal was shown to involve the recruitment and activation of several kinases, including Lyn, Syk, Akt and ERK. More recently, we showed that this antiapoptotic BCR signal can be completely abrogated with the selective small-molecule Syk inhibitor R406, suggesting that the Syk kinase could be a potential target for therapeutic intervention 13 .
In addition to blocking the antiapoptotic BCR signal, we observed that R406 is also moderately cytotoxic for unstimulated CLL cells 13 . This effect of R406 was related to inhibition of the increased basal activity of Syk, a phenomenon that was recently described in CLL and several other B-cell malignancies and shown to contribute to the increased apoptosis For personal use only. on April 19, 2017 . by guest www.bloodjournal.org From resistance of the malignant lymphocytes [13] [14] [15] [16] [17] [18] [19] [20] . The reason for the increased basal Syk activity in CLL B-cells is unclear at present, but could include persistent engagement of the BCR with autoantigen or exaggerated tonic BCR signaling due to mutations in regulatory BCR signaling components [21] [22] [23] .
The previous studies with R406 suggested that this compound could be even more active in vivo, where both antigen-dependent and constitutive BCR signals should co-operate to increase the survival and proliferation of the malignant B-cells. To test this possibility we have now evaluated the efficacy of R406 and its prodrug fostamatinib disodium (also called R788) in the Eμ-TCL1 transgenic mouse model of CLL 24 . Aged Eμ-TCL1 mice develop CD5+ B-cell leukemias that, like aggressive human CLL, show features of an antigen-driven process, including expression of stereotyped BCRs and reactivity with common autoantigens and microbial agents 25 . A particularly common reactivity of the TCL1 leukemias is against phosphatidylcholine (PtC), an autoantigen that is exposed on the surface of senescent erythrocytes and apoptotic cells. B cells with this specificity express BCRs that are encoded by one of two V H /Vκ combinations (VH11/Vκ9 or VH12/Vκ4/5H) and have been shown in numerous studies to be positively selected and expanded by antigen [26] [27] [28] [29] . Thus, TCL1 leukemias reactive with PtC should represent an excellent model to study the activity of compounds that target the BCR signaling pathway.
In the present study we show that treatment with R788 selectively inhibits the growth of TCL1 leukemias in vivo, without affecting the production of normal B lymphocytes.
Importantly, we show that R788 is effective against TCL1 leukemias with anti-PtC specificity, suggesting that R788 functions, at least in part, by inhibiting antigen-dependent BCR signaling. These data further underscore the relevance of the BCR signaling pathway as a potential therapeutic target in CLL and suggest that CLL should be a particularly appropriate setting for future clinical trials with R788 and other Syk inhibitors.
MATERIALS AND METHODS

Mouse models, TCL1 leukemia lines and adoptive cell transfer experiments
Eμ-TCL1 transgenic mice, kindly provided by Dr. Carlo Croce (Ohio State University, Columbus, OH), were backcrossed for seven generations on a C57Bl/6 background. All animal procedures were performed in accordance with Italian national and ICGEB institutional /ml).
The TCL1 leukemia lines that were used in the adoptive transfer experiments had been established from the original Eμ-TCL1 transgenic colony, which had a B6/C3H background.
For this reason the adoptive transfer experiments with these leukemias were done in B6/C3H F1 recipients (6-8 weeks old female mice; Harlan Laboratories B.V., Horst, The Netherlands).
For adoptive transfer 1.5x10 7 TCL1 leukemia cells were thawed, resuspended in 500 μL of phosphate-buffered saline (PBS) and injected intraperitoneally into the syngeneic recipients.
Mice were followed for leukemia development as described above and were euthanized when they developed signs and symptoms of a moribund state, such as lethargy, aversion to activity, lack of sustained purposeful response to gentle stimuli, shallow or labored breathing and other disabling symptoms. All animal procedures were performed in accordance with
Italian national (Italian legislative decree 116/92 and European directive 8/609) and ICGEB institutional guidelines.
Purification, immunophenotyping and culture of TCL1 leukemias and normal B cells
Mononuclear cells were separated from spleens of normal or leukemic mice by Ficoll gradient centrifugation (Amersham Biosciences, Uppsala, Sweden). Normal B-cells were purified by negative selection using the EasySep mouse B cell enrichment kit or positive selection using the EasySep mouse CD19 selection kit (both from StemCell Technologies, Meylan, France).
The purity of the selected populations was evaluated by staining with anti-CD5 PEconjugated and anti-B220 FITC-conjugated antibodies (BD Biosciences, Franklin Lakes, NJ),
followed by flow cytometry analysis on a FACSCalibur flow cytometer (BD Biosciences). The purity of the positively selected samples always exceeded 96%, the purity of the negatively selected samples ranged from 82% to 87%. TCL1 leukemia cells were usually not purified further, because they represented more than 90% of the mononuclear cell population isolated from the spleens of leukemic animals. However, for analysis of ZAP-70 expression by . The R406 prodrug R788 was prepared as a 4 mg/ml solution in 0.1% carboxymethylcellulose sodium, 0.1% methylparaben, 0.02% propylparaben, pH 6.5. The same vehicle without R788 was administered to the animals in the control groups.
Assessment of tumor burden
Spleen and two pairs of lymph nodes (inguinal and axillary) were collected from each mouse to assess the effect of R788 treatment on tumor burden. Single-cell suspensions were prepared from all samples and counted on a Hemavet HV950FS hematology analyzer. Red blood cells were lysed using RBC lysis buffer (155 mM NH 4 Cl, 10 mM KHCO 3 ).
IgV H gene sequence analysis
PCR amplification and sequencing of IgV H region genes were done as described elsewhere 25 .
Briefly, RNA was reverse transcribed using random hexamers and then PCR amplified with consensus FR1 family-specific primers in combination with a Cµ reverse primer. PCR 
Apoptosis and proliferation assays
To evaluate the cytotoxic effect of R406 in vitro, TCL1 leukemia cells (1x10 
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In vivo 5-bromo-2-deoxyuridine (BrdU) labeling was done in animals with adoptively transferred leukemia that were treated for 7 days with vehicle control or R788. On the last day of treatment each mouse received 20 mg/mL BrdU (BD Biosciences), in two divided doses during a 3 hour interval. Spleen samples were collected six hours after the second administration of BrdU. Frozen spleen sections were stained with the BrdU In-Situ Detection Kit (BD Biosciences), according to the instructions of the manufacturer. BrdU positive cells were counted as described for the TUNEL assay.
Statistical analysis
Student t tests and Mann-Whitney rank sum tests were performed to determine the significance of the differences between mean and median values as appropriate. The survival curves and medians were calculated within subgroups with the method of Kaplan-Meier. The log-rank test was used to compare differences between estimated survival curves. All statistical analyses were performed using the SigmaStat 3.1 program (Systat Software, Richmond, CA). P values are indicated in the figures.
RESULTS
R406 inhibits ligand-dependent and ligand-independent BCR signaling in TCL1 leukemias in vitro
We started our study by investigating whether TCL1 leukemias express constitutively active Syk, as previously described for human CLL. Significant phosphorylation of Syk at the activating Y352 and YY525/526 residues was observed in 2 of the 6 investigated leukemias (TCL1-002 and TCL-540 in Figure 1A ) and distal (phosphorylation of Akt, GSK3, FOXO and ERK) signaling events ( Figure 1C) . Interestingly, an increase in the amount of Syk phosphorylated at Y352 was observed in these experiments at higher R406 concentrations. Since this site in Syk is phosphorylated by Lyn, the most likely explanation for this finding is that Syk is involved in a negative regulatory circuit that inactivates Lyn after BCR engagement. Consistent with this possibility we observed that phosphorylation of Lyn at the activating Y397 residue increases in anti-IgM stimulated cells when Syk is inhibited by R406.
Since R406 has been shown to induce apoptosis in unstimulated human CLL cells, we next investigated whether it will have the same effect on TCL1 leukemias in vitro 13 . As shown in Figure 2 , a modest decrease in the percentage of viable (Annexin V/PI negative) cells was observed at the highest R406 concentrations. However, a similar rate of apoptosis was observed with normal mouse B-cells, suggesting that R406 is not selectively cytotoxic to the leukemic cells, despite the higher levels of constitutively active Syk. This was especially evident with the leukemic line TCL1-002, which expressed high levels of phospho-Syk, but appeared most resistant to the cytotoxic effect of R406.
Induction of apoptosis by R406 and other Syk inhibitors in primary human CLL cells has been associated with downregulation of the antiapoptotic protein Mcl-1 13, 20 . During the course of this study we observed that R406 also upregulates the proapoptotic protein Bim in human CLL cells ( Figure 2C and data not shown). Induction of Bim was also observed in some of the TCL1 leukemias, but this was not accompanied by a decrease in Mcl-1 expression. Rather, a slight increase in Mcl-1 levels was occasionally observed at higher R406 concentrations, suggesting that expression of this antiapoptotic protein may be subject to different regulatory and possibly compensatory mechanisms in TCL1 leukemia cells.
R788 inhibits the growth of adoptively transferred TCL1 leukemias in vivo
Although R406 was not markedly cytotoxic to the leukemic cells in vitro, the possibility remained that this compound could be more active in vivo, where it could potentially inhibit antigen-induced BCR signals. To test this possibility, we investigated the activity of the R406 prodrug R788 against adoptively transferred TCL1 leukemias. The TCL1 leukemias are particularly appropriate for this purpose, since they can be propagated with 100% efficiency in syngeneic mouse recipients 25, 30 , despite the fact that they are not immortalized and do not grow in vitro. In addition, in a previous study we showed that the BCR of TCL1-002 cells binds to PtC 25 , suggesting that at least in the case of this leukemia the malignant B cells should be continuously exposed to antigen following adoptive transfer.
To assess the activity of R788 against TCL1-002 leukemia, 1.5x10 7 cells were adoptively transferred in 18 syngeneic recipients by intraperitoneal injection. Three days later treatment was initiated with R788 in 8 mice, whereas the remaining 10 animals were given vehicle control. R788, which is rapidly converted to R406 following intraperitoneal administration, was given during 18 consecutive days at a daily dose of 80 mg/kg (this dose had been established as the maximum tolerated dose in previous mouse toxicity studies 31 ).
Because the plasma half-life of R406 in mice is less than 2 hours (Supplementary Figure 1 and reference 17) we decided to administer R788 in 3 divided doses at 3 hour intervals, as to provide several hours of continuous Syk inhibition during each day of treatment. We considered that this dosing schedule will more accurately reflect the situation in humans, where Syk inhibition is sustained because of the substantially longer plasma half-life of R406 (15 hours Treatment with R788 significantly prolonged the survival of the studied animals.
Median survival of control group animals with TCL1-002 leukemia was 46 days, whereas median survival of R788-treated animals was 172 days ( Figure 3B ). Similarly, control group animals with TCL1-551 leukemia had a median survival of 45 days, whereas median survival was not reached at 170 days in the R788 group. The animals with TCL1-870 leukemia were studied more recently and therefore survival data were not available. To determine whether R788 will also affect the migration of the malignant lymphocytes we performed a new experiment in which we monitored changes in circulating leukemia cells during the first 15 days of R788 treatment. In contrast to the previous experiment, this experiment was performed with animals that had detectable leukemia cells in the peripheral blood when treatment was initiated. Interestingly, after 4 days of treatment animals receiving R788 showed a greater rise in the number of circulating malignant lymphocytes than controls ( Figure 4A ). This rise was associated with a decrease in the number of lymphocytes in spleen and lymph nodes ( Figure 4B ), suggesting that it was caused by relocation of the malignant cells from the tissues into the blood. Consistent with this explanation, subsequent analysis at days 7, 10 and 15 showed a dramatic rise in the number of circulating leukemic cells in the control group, whereas the number of circulating leukemic cells in the R788 group remained 
R788 blocks BCR signaling and inhibits leukemic cell survival and proliferation in vivo
To further explore the mechanisms of R788 action we performed another set of experiments in which we evaluated the effects of R788 on BCR signaling, leukemic cell proliferation and survival. These experiments were performed with animals that were allowed to develop overt TCL1-002 leukemias before starting treatment (usually 28 days after adoptive transfer).
Animals were sacrificed after 7 days of R788 treatment and PB and spleen samples were collected for subsequent analysis. As shown in Figure 5A , R788 effectively inhibited BCR signaling in vivo, as evidenced by a significant reduction in the amount of phosphorylated 
R788 inhibits the growth of spontaneously developing TCL1 leukemias
We next investigated whether R788 will also be effective against spontaneously developing TCL1 leukemias. For this experiment we selected eight Eμ-TCL1 transgenic mice that prior to treatment showed a steady rise in both the percentage and the absolute number of whereas it continued to progress under therapy in two other mice (TCL1-275 and TCL1-104).
One month after therapy was discontinued the number of leukemic cells rose to pretreatment or higher levels in 6 animals, whereas they remained low or continued to fall in two mice (TCL1-093 and TCL1-121, respectively). In TCL1-121 there was almost complete treatment also did not correlate with the amount of phospho-Syk or the in vitro sensitivity to R406, which was equal between the responding and nonresponding cases ( Figure 7A, 7B and Table 1 ). In addition, all TCL1 leukemias were ZAP-70-negative and CD38-positive, suggesting that the response to R788 treatment is not related to the expression of these two important prognostic factors ( Figure 7C , Table 1 and Supplementary Figure 3) . Collectively, these data suggest that other factors underlie the resistance of some of these leukemias to R788 treatment.
DISCUSSION
Chronic or recurrent antigen-stimulation is considered to play a key role in the development and progression of several B-cell malignancies, including CLL, Helicobacter Pylori-associated gastric MALT lymphomas and certain indolent lymphomas associated with chronic hepatitis C virus infection [1] [2] [3] [34] [35] [36] . In the case of Helicobacter Pylori and hepatitis C virus-associated lymphomas the pathogenic role of antigen is further corroborated by clinical studies, which have shown that elimination of the infectious agent can lead to tumor regression in patients with early stages of the disease [37] [38] [39] . Although attractive, this approach can not be applied to
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An alternative strategy to disrupt antigen-receptor signaling in CLL would be to block BCR signal transduction using small molecule inhibitors. This approach was tested in the current study using the selective Syk inhibitor R788 and the Eμ-TCL1 transgenic mouse model of CLL. The leukemias that develop in Eμ-TCL1 transgenic mice are currently the most widely used preclinical model to study the activity of novel therapeutic agents for CLL 30, [43] [44] [45] .
There is amounting evidence that these leukemias are antigen-driven, suggesting that they should be especially suitable for testing agents that target the BCR signaling pathway. As is the case with human CLL, these leukemias frequently express stereotyped BCRs that bind to neoantigens exposed on the surface of senescent or apoptotic cells 25 , which was also observed in our present study. In addition, recent studies have shown that disruption of genes involved in BCR signal transduction prevents or significantly delays the development of these leukemias, further suggesting a role for antigen stimulation during the expansion of the malignant clones 46, 47 .
In the current study we show that R788 is highly active in two Eμ-TCL1 leukemia models, i.e. adoptively transferred TCL1 leukemias and leukemias that spontaneously develop in Eμ-TCL1 transgenic mice. Treatment with R788 inhibited both the proliferation and the survival of the malignant B-cells, leading to eradication of the malignant clones in a considerable proportion of animals with adoptively transferred leukemia. It is noteworthy that these effects were observed following relatively short treatments with R788, lasting from 18 to a maximum of 45 days.
The primary mechanism of R788 action appeared to be inhibition of antigen-dependent BCR signaling, rather than inhibition of constitutive Syk activity, for several reasons. First, R788 was equally effective against leukemias with high or low basal levels of phosphorylated Syk, including leukemias that expressed the same amount of active Syk as normal B-cells.
Second, R788 selectively inhibited the growth of the malignant clones and had almost no effect on the normal B-cell population, despite the equal or even greater sensitivity of the latter to the cytotoxic effect of this compound in vitro. Third, the cytotoxic effect of R406 in vitro was relatively modest and occurred at high R406 concentrations to which the cells were
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The arguments presented above do not entirely exclude the possibility that the therapeutic effect of R788 was to some extent also due to inhibition of antigen-independent BCR signals. In this respect, R788 was recently shown to reduce the tumor burden and prolong the survival of mice transplanted with Non-Hodgkin lymphomas (NHL) that develop in the absence of antigen stimulation (Eμ-MYC/IgHEL transgenic mice), suggesting that inhibition of the tonic BCR signal could be therapeutically effective in certain B-cell malignancies 17 . It is worth noting, however, that R788 was ineffective in preliminary experiments with the TCL1-002 leukemia when the drug was administered once a day, as in the case of the Eμ-MYC/IgHEL study, or twice a day at 8-10 hour intervals (data not shown).
Rather, in the case of the TCL1 leukemias repeated administrations of the drug providing several hours of continuous Syk inhibition were required for growth inhibition, suggesting that the BCR signals targeted by R788 in these two models are qualitatively and/or quantitatively different.
R788 was recently tested in phase II clinical trials of rheumatoid arthritis, immune thrombocytopenic purpura and recurrent B cell NHL, where it showed considerable clinical activity in the absence of significant toxicities or side effects [48] [49] [50] . Interestingly, the NHL trial included a small series of patients with SLL/CLL, which showed by far the highest response rate (55%) 50 . This study also showed that normal B cells are not affected by R788 in vivo, in parallel to the situation observed in our mouse model. The encouraging data from the NHL clinical trial together with the results of our current study suggest that CLL should be a particularly appropriate setting for future clinical trials with R788. There is substantial rationale to investigate R788 in combination with chemotherapy, considering that BCR engagement can increase the resistance of the leukemic cells to fludarabine-induced apoptosis 11 and can enhance their homing and retention to the protective tissue microenvironments 18 . Another approach worth investigating would be to use R788 as consolidation therapy, especially considering that this compound appeared particularly effective in treating TCL1 leukemias with low tumor burden.
Leukemias resistant to R788 were observed both in the clinical trial by Friedberg et al 50 and in our animal model. The nonresponding TCL1 leukemias did not appear to differ in
expressed BCRs with features typical of anti-PtC antibodies were identified. In addition, all TCL1 leukemias expressed unmutated IgV H genes and were ZAP-70-negative and CD38-positive, suggesting that the response to R788 is not related to the expression of these prognostic factors. Thus, other factors will have to be considered to account for the variability in the response, such as mutations that render the malignant clones independent of BCR signals or differences in the degree of Syk inhibition. The latter possibility requires consideration particularly in the animal model, given the short plasma half-life of R406 in mice and the apparent requirement for sustained Syk inhibition. In the NHL trial no correlation between R406 pharmacokinetics and clinical outcome was detected 50 , but analysis of the degree of Syk inhibition in a few patients from the ITP trial identified differences that appeared to correlate with the platelet response 49 . Thus, further pharmacokinetic and pharmacodynamic studies appear warranted and may provide useful information on the mechanisms that determine the response to R788.
In summary, the data presented in this study demonstrate that disruption of BCR signaling can selectively inhibit the proliferation and survival of the malignant B-cells in the Eμ-TCL1 transgenic mouse model of CLL. Considering the similarities between the mouse model and the human disease, these data provide further rationale for clinical trials with R788 in CLL and establish the BCR signaling pathway as a potential therapeutic target in this disease.
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